EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double‐Blind, Placebo‐Controlled Trial

Mathias E Cook iD, Cecilie S Knoph iD, Line Davidsen iD, Jens B Frøkjær iD, Niels H Bruun iD, Srdan Novovic iD, Amer Hadi, Maiken Thyregod Jørgensen iD, Michael B Mortensen iD, Ove Schaffalitzky iD, Liv B J Nielsen, Mark Berner-Hansen iD und 2 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70178 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Mathias E Cook und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Naltrexone, Pancreatitis, Narcotic Antagonists, Secondary Prevention. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Fonden, Health Research Foundation of North Denmark Region, Shionogi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims No medications are currently approved for the prevention of recurrent acute pancreatitis. This trial evaluated whether naldemedine, a peripherally acting μ ‐opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis.

Methods

This was a multicentre, double‐blinded, placebo‐controlled randomised trial conducted at four Danish pancreatitis referral centres. Participants aged 18–75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months. The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria. Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life. At the end of follow‐up, the participant's global impression of change, safety and tolerability outcomes, new‐onset diabetes and pancreatic exocrine insufficiency were assessed.

Results

74 participants (mean age: 46 years; 41% female) were randomised to naldemedine ( n = 36) or placebo ( n = 38). During a median follow‐up time of 365 days (IQR, 352–370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29–1.01; p = 0.05). No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes. Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24–0.97; p = 0.04).

Conclusions

Treatment with naldemedine was safe and well‐tolerated and may reduce the risk of recurrent acute pancreatitis. A larger confirmatory trial is needed to verify these findings.

Trial registration

ClinicalTrials.gov Identifier: PAMORA‐RAP: NCT04966559

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexonePancreatitisNarcotic AntagonistsSecondary PreventionHumansFemaleMiddle AgedMaleAdultDouble-Blind MethodAgedDenmarkQuality of LifeYoung AdultAdolescentTreatment OutcomeRecurrenceReceptors, Opioid, muAcute Disease

Stichwörter der Autor:innen

PAMORARCTnaldemedineopioid receptorsrecurrent acute pancreatitis

Substanzen

NaltrexoneNarcotic AntagonistsnaldemedineReceptors, Opioid, mu

Autor:innen und Institutionen

  • Centre for Pancreatic Diseases and Mech-Sense, Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Radiology, Aalborg University Hospital, Aalborg, Denmark.
  • Research Data and Biostatistics, Aalborg University Hospital, Aalborg, Denmark.
  • Gastrounit, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  • Department of Internal Medicine, SLB Vejle Hospital, Vejle, Denmark.

ORCID-Profile: Mathias E Cook, Cecilie S Knoph, Line Davidsen, Jens B Frøkjær, Niels H Bruun, Srdan Novovic, Maiken Thyregod Jørgensen, Michael B Mortensen, Ove Schaffalitzky, Mark Berner-Hansen, Asbjørn M Drewes, Søren S Olesen

Förderung

  • Novo Nordisk Fonden
  • Health Research Foundation of North Denmark Region
  • Shionogi

Zitieren

APA

Cook, M. E., Knoph, C. S., Davidsen, L., Frøkjær, J. B., Bruun, N. H., Novovic, S., Hadi, A., Jørgensen, M. T., Mortensen, M. B., Schaffalitzky, O., Nielsen, L. B. J., Berner-Hansen, M., Drewes, A. M., & Olesen, S. S. (2026). Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double‐Blind, Placebo‐Controlled Trial. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70178

Vancouver

Cook ME, Knoph CS, Davidsen L, Frøkjær JB, Bruun NH, Novovic S, et al. Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double‐Blind, Placebo‐Controlled Trial. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70178

BibTeX
@article{Cook2026,
  author = {Cook, Mathias E and Knoph, Cecilie S and Davidsen, Line and Frøkjær, Jens B and Bruun, Niels H and Novovic, Srdan and Hadi, Amer and Jørgensen, Maiken Thyregod and Mortensen, Michael B and Schaffalitzky, Ove and Nielsen, Liv B J and Berner-Hansen, Mark and Drewes, Asbjørn M and Olesen, Søren S},
  title = {Naldemedine for the Prevention of Recurrent Acute Pancreatitis: A Randomised, Double‐Blind, Placebo‐Controlled Trial},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70178}
}
Kostenlos starten →